← FDA Drug Approvals (Drugs@FDA)

BIVALIRUDIN

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: ACCORD HLTHCARE · Approved 2017-11-22

Drug application

FDA Application #

ANDA206551

Application type

Abbreviated New Drug Application (Generic)

Brand name

BIVALIRUDIN

Generic name

BIVALIRUDIN

Active ingredients

BIVALIRUDIN

Dosage form

INJECTABLE

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

ACCORD HLTHCARE

Manufacturer

Accord Healthcare, Inc.

First approval

2017-11-22

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown